Antiviral favipiravir brings stunning gains to Glenmark, almost equal to the entire India sales of some multinationals, as demand surged amid the ferocious second of COVID-19 in the country. Such brand build-up could have taken five to seven years in pre-pandemic times, experts said.
It’s not everyday that a pharma brand in India that’s been on the market for under 12 months goes on to emerge as the top-selling therapy in the retail market with a significant lead over the number two ranked product.
That’s the kind of stunning run Glenmark Pharmaceuticals Limited’s Fabiflu (favipiravir) has had, garnering sales of INR7
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.
Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.
